Nicholas W. Wood, MbChB, PhD, FRCP, FMedSci, UCL Queen Square Institute of Neurology, London, UK, discusses the use of genetics and genomic data to stratify and refine disease classification in the neurology space. For instance, not every patient with Parkinson's disease has the same molecular root cause. Personalized medicine aims to offer specific treatments tailored to individual patients, while precision medicine focuses on identifying subgroups within a disease, such as Parkinson's patients with specific genetic backgrounds or coexisting conditions. Prof. Wood emphasizes the importance of using genetics to break down and define these groups for more targeted and effective treatments. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
